Literature DB >> 226702

Cellular antiproliferative action exerted by auranofin.

T M Simon, D H Kunishima, G J Vibert, A Lorber.   

Abstract

Auranofin (AF) is a new orally absorbed coordinated gold compound currently undergoing Phase I studies for its use in the treatment of rheumatoid arthritis. Our investigations with RAJI lymphoma, HeLa carcinoma, and EBV-transformed cells indicate AF exerts an inhibitory effect on DNA, RNA, and protein synthesis as assessed by 3H-thymidine, 3H-uridine, and 3H-leucine uptake, respectively. A rapid and persistent dose dependent inhibition of 3H-thymidine uptake was observed at gold concentrations of 50-100 microgram/dl while all parameters were inhibited after a 24 hr exposure to 100 microgram/dl. Reductions in viability and surface morphological changes were also observed. These results suggest AF exerts a significant inhibitory effect on essential biological processes and functions.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 226702

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN： 0380-0903


  10 in total

1.  Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation.

Authors:  Sandra Craig; Lei Gao; Irene Lee; Thomas Gray; Anthony J Berdis
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

2.  Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer.

Authors:  Tiziano Marzo; Lara Massai; Alessandro Pratesi; Matteo Stefanini; Damiano Cirri; Francesca Magherini; Matteo Becatti; Ida Landini; Stefania Nobili; Enrico Mini; Olivia Crociani; Annarosa Arcangeli; Serena Pillozzi; Tania Gamberi; Luigi Messori
Journal:  ACS Med Chem Lett       Date:  2019-02-07       Impact factor: 4.345

Review 3.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

4.  A comparison of the effects of two gold-containing therapeutic agents on articular chondrocyte growth in vitro.

Authors:  C J Kirkpatrick; W Mohr
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

5.  The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy.

Authors:  Vesna Milacic; Q Ping Dou
Journal:  Coord Chem Rev       Date:  2009       Impact factor: 22.315

6.  Gold salts inhibit osteoclastic bone resorption in vitro.

Authors:  T J Hall; H Jeker; H Nyugen; M Schaeublin
Journal:  Inflamm Res       Date:  1996-05       Impact factor: 4.575

7.  Effect of auranofin on antibody-dependent cellular cytotoxicity (ADCC) mediated by rat peripheral blood polymorphonuclear leukocytes and mononuclear cells.

Authors:  M J DiMartino; D T Walz
Journal:  Inflammation       Date:  1980-09       Impact factor: 4.092

Review 8.  Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV.

Authors:  Christina Gavegnano; Andrea Savarino; Taofeek Owanikoko; Vincent C Marconi
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

9.  Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs.

Authors:  Lauren Fernandez-Vega; Valeria A Ruiz Silva; Tania M Domínguez-González; Sebastián Claudio-Betancourt; Rafael E Toro-Maldonado; Luisa C Capre Maso; Karina Sanabria Ortiz; Jean A Pérez-Verdejo; Janeishly Román González; Grecia T Rosado-Fraticelli; Fabiola Pagán Meléndez; Fabiola M Betancourt Santiago; Daniel A Rivera-Rivera; Carlos Martínez Navarro; Andrea C Bruno Chardón; Axel O Vera; Arthur D Tinoco
Journal:  Inorganics (Basel)       Date:  2020-01-26

10.  Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System.

Authors:  Damiano Cirri; Tanja Schirmeister; Ean-Jeong Seo; Thomas Efferth; Lara Massai; Luigi Messori; Nicola Micale
Journal:  Molecules       Date:  2020-09-28       Impact factor: 4.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.